A Phase II Study Of PS-341 In Metastatic Non-Small Cell Lung Cancer

Trial Profile

A Phase II Study Of PS-341 In Metastatic Non-Small Cell Lung Cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 15 Jan 2013

At a glance

  • Drugs Bortezomib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Most Recent Events

    • 15 Jan 2013 Primary endpoints added as reported by ClinicalTrials.gov.
    • 15 Jan 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 22 Aug 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top